Connection

GUILLERMINA LOZANO to Male

This is a "connection" page, showing publications GUILLERMINA LOZANO has written about Male.
Connection Strength

0.312
  1. p53 drives a transcriptional program that elicits a non-cell-autonomous response and alters cell state in vivo. Proc Natl Acad Sci U S A. 2020 09 22; 117(38):23663-23673.
    View in: PubMed
    Score: 0.022
  2. Men1 maintains exocrine pancreas homeostasis in response to inflammation and oncogenic stress. Proc Natl Acad Sci U S A. 2020 03 24; 117(12):6622-6629.
    View in: PubMed
    Score: 0.021
  3. Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes. Oncogene. 2018 01 18; 37(3):332-340.
    View in: PubMed
    Score: 0.018
  4. Tumorigenesis promotes Mdm4-S overexpression. Oncotarget. 2017 Apr 18; 8(16):25837-25847.
    View in: PubMed
    Score: 0.017
  5. The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis. J Pathol. 2017 03; 241(4):501-510.
    View in: PubMed
    Score: 0.017
  6. Distinct downstream targets manifest p53-dependent pathologies in mice. Oncogene. 2016 11 03; 35(44):5713-5721.
    View in: PubMed
    Score: 0.016
  7. Therapeutic efficacy of p53 restoration in Mdm2-overexpressing tumors. Mol Cancer Res. 2014 Jun; 12(6):901-11.
    View in: PubMed
    Score: 0.014
  8. The p53-Mdm2 network in progenitor cell expansion during mouse postnatal development. J Pathol. 2007 Dec; 213(4):360-8.
    View in: PubMed
    Score: 0.009
  9. Mtbp haploinsufficiency in mice increases tumor metastasis. Oncogene. 2008 Mar 20; 27(13):1813-20.
    View in: PubMed
    Score: 0.009
  10. Mammary tumor modifiers in BALB/cJ mice heterozygous for p53. Mamm Genome. 2007 May; 18(5):300-9.
    View in: PubMed
    Score: 0.009
  11. Loss of Mdm4 results in p53-dependent dilated cardiomyopathy. Circulation. 2007 Jun 12; 115(23):2925-30.
    View in: PubMed
    Score: 0.009
  12. A genetic mouse model for metastatic lung cancer with gender differences in survival. Oncogene. 2007 Oct 18; 26(48):6896-904.
    View in: PubMed
    Score: 0.009
  13. Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer. Elife. 2024 Aug 30; 13.
    View in: PubMed
    Score: 0.007
  14. Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets. Cancer Res. 2003 Dec 15; 63(24):8664-9.
    View in: PubMed
    Score: 0.007
  15. Modelling aggressive prostate cancers of young men in immune-competent mice, driven by isogenic Trp53 alterations and Pten loss. Cell Death Dis. 2022 09 08; 13(9):777.
    View in: PubMed
    Score: 0.006
  16. A Blood-based Polyamine Signature Associated With MEN1 Duodenopancreatic Neuroendocrine Tumor Progression. J Clin Endocrinol Metab. 2021 11 19; 106(12):e4969-e4980.
    View in: PubMed
    Score: 0.006
  17. Organization, expression, and localization of the murine mdmx gene and pseudogene. Gene. 2001 May 30; 270(1-2):277-83.
    View in: PubMed
    Score: 0.006
  18. p73 gene alterations and expression in primary oral and laryngeal squamous carcinomas. Carcinogenesis. 2001 May; 22(5):729-35.
    View in: PubMed
    Score: 0.006
  19. The Common Germline TP53-R337H Mutation Is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model. Cancer Res. 2021 05 01; 81(9):2442-2456.
    View in: PubMed
    Score: 0.006
  20. High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci U S A. 2000 Apr 11; 97(8):4174-9.
    View in: PubMed
    Score: 0.005
  21. Identification of cancer sex-disparity in the functional integrity of p53 and its X chromosome network. Nat Commun. 2019 11 26; 10(1):5385.
    View in: PubMed
    Score: 0.005
  22. Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice. J Pathol. 1999 Jul; 188(3):322-8.
    View in: PubMed
    Score: 0.005
  23. Constitutive Dicer1 phosphorylation accelerates metabolism and aging in vivo. Proc Natl Acad Sci U S A. 2019 01 15; 116(3):960-969.
    View in: PubMed
    Score: 0.005
  24. Exclusion of a p53 germline mutation in a classic Li-Fraumeni syndrome family. Hum Genet. 1998 Jun; 102(6):681-6.
    View in: PubMed
    Score: 0.005
  25. A spontaneous model of spondyloarthropathies that develops bone loss and pathological bone formation: A process regulated by IL27RA-/- and mutant-p53. PLoS One. 2018; 13(3):e0193485.
    View in: PubMed
    Score: 0.005
  26. Spatio-Temporal Genomic Heterogeneity, Phylogeny, and Metastatic Evolution in Salivary Adenoid Cystic Carcinoma. J Natl Cancer Inst. 2017 10 01; 109(10).
    View in: PubMed
    Score: 0.004
  27. The Li-Fraumeni syndrome: an inherited susceptibility to cancer. Mol Med Today. 1997 Sep; 3(9):390-5.
    View in: PubMed
    Score: 0.004
  28. Novel MYBL1 Gene Rearrangements with Recurrent MYBL1-NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations. Clin Cancer Res. 2016 Feb 01; 22(3):725-33.
    View in: PubMed
    Score: 0.004
  29. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature. 1995 Nov 09; 378(6553):203-6.
    View in: PubMed
    Score: 0.004
  30. Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner. Cell Cycle. 2013 Jun 01; 12(11):1722-31.
    View in: PubMed
    Score: 0.003
  31. AACR Cancer Progress Report 2012. Clin Cancer Res. 2012 Nov 01; 18(21 Suppl):S1-100.
    View in: PubMed
    Score: 0.003
  32. Mutant p53 disrupts role of ShcA protein in balancing Smad protein-dependent and -independent signaling activity of transforming growth factor-? (TGF-?). J Biol Chem. 2011 Dec 23; 286(51):44023-44034.
    View in: PubMed
    Score: 0.003
  33. Differential gene expression profiling of aggressive and nonaggressive follicular carcinomas. Hum Pathol. 2011 Sep; 42(9):1213-20.
    View in: PubMed
    Score: 0.003
  34. Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J Clin Invest. 2011 Mar; 121(3):893-904.
    View in: PubMed
    Score: 0.003
  35. Joint effects of germ-line TP53 mutation, MDM2 SNP309, and gender on cancer risk in family studies of Li-Fraumeni syndrome. Hum Genet. 2011 Jun; 129(6):663-73.
    View in: PubMed
    Score: 0.003
  36. Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers. J Clin Invest. 2011 Mar; 121(3):851-65.
    View in: PubMed
    Score: 0.003
  37. p53 status in stromal fibroblasts modulates tumor growth in an SDF1-dependent manner. Cancer Res. 2010 Dec 01; 70(23):9650-8.
    View in: PubMed
    Score: 0.003
  38. Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations. PLoS One. 2010 May 26; 5(5):e10813.
    View in: PubMed
    Score: 0.003
  39. A deficiency in Mdm2 binding protein inhibits Myc-induced B-cell proliferation and lymphomagenesis. Oncogene. 2010 Jun 03; 29(22):3287-96.
    View in: PubMed
    Score: 0.003
  40. An information-theoretic analysis of genetics, gender and age in cancer patients. PLoS One. 2008 Apr 09; 3(4):e1951.
    View in: PubMed
    Score: 0.002
  41. HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. Mod Pathol. 2007 Jan; 20(1):54-62.
    View in: PubMed
    Score: 0.002
  42. Genetic mapping of a putative tumor suppressor locus that influences tumorigenesis and metastasis in mice. Genes Chromosomes Cancer. 2006 Jul; 45(7):668-75.
    View in: PubMed
    Score: 0.002
  43. Genetic mapping of a third Li-Fraumeni syndrome predisposition locus to human chromosome 1q23. Cancer Res. 2005 Jan 15; 65(2):427-31.
    View in: PubMed
    Score: 0.002
  44. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004 Nov 24; 119(5):591-602.
    View in: PubMed
    Score: 0.002
  45. Germ line BAX alterations are infrequent in Li-Fraumeni syndrome. Cancer Epidemiol Biomarkers Prev. 2004 Aug; 13(8):1403-6.
    View in: PubMed
    Score: 0.002
  46. Novel p53 germline mutation in a patient with Li-Fraumeni syndrome. Intern Med J. 2003 Dec; 33(12):621.
    View in: PubMed
    Score: 0.002
  47. Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. Hum Genet. 2003 Aug; 113(3):238-43.
    View in: PubMed
    Score: 0.002
  48. Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet. 2003 Apr; 72(4):975-83.
    View in: PubMed
    Score: 0.002
  49. Germ cell expression of an isolated human endogenous retroviral long terminal repeat of the HERV-K/HTDV family in transgenic mice. J Virol. 1999 Dec; 73(12):9976-83.
    View in: PubMed
    Score: 0.001
  50. The p38MAPK inhibitor SB203580 alleviates ultraviolet-induced phosphorylation at serine 389 but not serine 15 and activation of p53. Biochem Biophys Res Commun. 1999 Aug 02; 261(2):464-71.
    View in: PubMed
    Score: 0.001
  51. TP53 mutation and haplotype analysis of two large African American families. Hum Mutat. 1999; 14(3):216-21.
    View in: PubMed
    Score: 0.001
  52. Effective treatment of early endobronchial cancer with regional administration of liposome-p53 complexes. J Natl Cancer Inst. 1998 Aug 05; 90(15):1130-7.
    View in: PubMed
    Score: 0.001
  53. Bcl-2 inhibits p53 nuclear import following DNA damage. Oncogene. 1997 Dec 04; 15(23):2767-72.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.